https://www.bbc.com/news/world-latin-america-57211
Post# of 148152
Cytodyn has to stay with it and get their work done. It's apparent that any real success for Vyrologix may need to happen overseas before the US. It is awful to see, but that is the nature of investing in biotech. It's often the solution in search of a problem, as well as a problem in search of a solution. Argentina shares a border with Brazil.